Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DOT1L/H3K79me2 represses HIV-1 reactivation via recruiting DCAF1.
Liang F, Jin J, Li Q, Duan J, Jiang A, Chen X, Geng H, Wu K, Yu F, Zhao X, Zhou Y, Hu D, Chen L. Liang F, et al. Among authors: jin j. Cell Rep. 2024 Jul 23;43(7):114368. doi: 10.1016/j.celrep.2024.114368. Epub 2024 Jun 20. Cell Rep. 2024. PMID: 38905100 Free article.
Author Correction: TNF inhibitors target a mevalonate metabolite/TRPM2/calcium signaling axis in neutrophils to dampen vasculitis in Behçet's disease.
Zhang M, Kang N, Yu X, Zhang X, Duan Q, Ma X, Zhao Q, Wang Z, Wang X, Liu Y, Zhang Y, Zhu C, Gao R, Min X, Li C, Jin J, Cao Q, Liu R, Bai X, Yang H, Zhao L, Liu J, Chen H, Zhang Y, Liu W, Zheng W. Zhang M, et al. Among authors: jin j. Nat Commun. 2025 Jan 3;16(1):366. doi: 10.1038/s41467-024-55702-z. Nat Commun. 2025. PMID: 39753557 Free PMC article. No abstract available.
Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma.
Ren Z, Shao G, Shen J, Zhang L, Zhu X, Fang W, Sun G, Bai Y, Wu J, Liu L, Yuan Y, Zhang J, Li Z, Zhang L, Yin T, Wu J, Hou X, Yu H, Li J, Wang Q, Zhu J, Fan J; Serplulimab-HCC Investigators. Ren Z, et al. Cancer Immunol Immunother. 2025 Jan 3;74(2):69. doi: 10.1007/s00262-024-03917-w. Cancer Immunol Immunother. 2025. PMID: 39751879 Free PMC article. Clinical Trial.
13,261 results
You have reached the last available page of results. Please see the User Guide for more information.